建議您使用以下瀏覽器觀看合一網站，
以獲得最佳瀏覽效果。
如何使用IE找到Microsoft Edge?
-
開啟新分頁(紅色框)
-
於搜尋框中打入Edge(紅色框)，並按搜尋(藍色框)
-
點擊【立即啟動】(藍框處)打開 Microsoft Edge
Title
Oneness Biotech to Present at the 41st Annual J.P. Morgan Healthcare Conference
Oneness announces the information about the investor's conference of 2022 Q4.
Oneness and Microbio (Shanghai) signed an agreement with Cho Pharma to jointly develop glycosylation-based nucleic acid delivery technology.
Oneness Biotech Co., Ltd. receives a Malaysian patent titled "TOPICAL FORMULATION FOR PROMOTING WOUND HEALING" on Fespixon cream (Research code: ON101).
Oneness has been invited for a poster presentation with on-site Q&A for the Phase 3 MRCT post-hoc analysis of the DFU new drug, Fespixon at IDF Congress 2022.
The post-market hard-to-heal cases treated by the DFU new drug, Fespixon have been accepted for an oral presentation at 2022 CDS
The trading of Oneness securities in centralized securities exchange market follows Announcement or Notice of Attention to Trading Information
The Board of Directors of Oneness has approved a donation to Teh-Tzer Study Group for Human Medical Research Foundation.
Announce the change of the corporate governance officer.
The Company's 2022Q3 consolidated financial statements have been approved by the Board of Directors
Oneness Biotech Co., Ltd. receives Israeli, Mexican and Hong Kong patents on the producing recombinant glycoproteins with modified glycosylation.
Fespixon's clinical meaningfulness as a macrophage- regulation new drug compared with other DFU treatments has been reviewed and published in Pharmaceutics.
Oneness announces the information about the investor's conference of 2022 Q3.
SNS812, a broad-spectrum siRNA co-developed by Oneness and Microbio (Shanghai) to treat SARS-CoV-2 infection, was greenlighted by FDA to proceed with a Ph1 study
The trading of Oneness securities in centralized securities exchange market follows Announcement or Notice of Attention to Trading Information
建議您使用以下瀏覽器觀看合一網站，
以獲得最佳瀏覽效果。
如何使用IE找到Microsoft Edge?